E

Emek Medical Center | Hematology Department

Research site
(Unclaimed)
Location
21 Yitzhak Rabin Street, Afula, HaTsafon, Israel
Site insights

Top conditions

Prostatic Cancer (2 trials)

Top treatments

MK-5684

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Trials

2 of 2
Status: Active
Trial type: Interventional
Funder type: Industry

Filters
3
A Study of MK-5684 Versus Alternative Next-generation Hormonal Agent (NHA) in Metastatic Castration-resistant Prostate Cancer (mCRPC) Post One NHA (MK-5684-004)

The purpose of this study is to assess the efficacy and safety of MK-5684 plus hormone replacement therapy (HRT) compared to alternative abiraterone...

Enrolling
Metastatic Castration-resistant Prostate Cancer (mCRPC)
Prostatic Neoplasms
Drug: Enzalutamide
Drug: Hydrocortisone

This is a phase 3, randomized, open-label study of MK-5684 compared to alternative abiraterone acetate or enzalutamide in participants with metastati...

Enrolling
Prostate Cancer Metastatic
Drug: Fludrocortisone acetate
Drug: Dexamethasone

Trial sponsors

Merck Sharp & Dohme (MSD) logo

Merck Sharp & Dohme (MSD) (2 trials)

Clinical trials

Find clinical trialsTrials by location

Resources

© Copyright 2024 Veeva Systems